ENPP2 and hepatocellular carcinoma: Moreover, studies by Erstad et al. (2017) showed in a rat model of hepatic fibrosis and hepatocellular carcinoma (HCC) that targeting the ATX-LPAR1 axis by inhibiting either ATX or LPAR1 decreased fibrosis and HCC development [69].